Accueil   Diary - News   All news Novasep Invests in a €27m Viral Vector Production Facility

Novasep Invests in a €27m Viral Vector Production Facility

The strategic investment supports the growing demand for development and commercial phase production of viral-vector based therapies


LYON, France, February 13, 2017b -- The new site, scheduled to be operational in early 2019, will be built at Novasep's facility in Seneffe, Belgium, to complement the existing lab-scale suites of the neighboring site in Gosselies.



The site will feature two cGMP suites on 2000 sqm. equipped with a set of single-use bioreactors ranging from 200L up to 2000L. It will fit perfectly with the production requirements for phase III and commercial stages.



Read the press release


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree